6.85
0.10 (1.48%)
| Penutupan Terdahulu | 6.75 |
| Buka | 6.79 |
| Jumlah Dagangan | 7,514 |
| Purata Dagangan (3B) | 22,750 |
| Modal Pasaran | 94,450,680 |
| Harga / Pendapatan (P/E TTM) | 32.62 |
| Harga / Pendapatan (P/E Ke hadapan) | 22.88 |
| Harga / Jualan (P/S) | 1.50 |
| Harga / Buku (P/B) | 23.54 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Dec 2025 |
| Margin Keuntungan | 8.26% |
| Margin Operasi (TTM) | -13.87% |
| EPS Cair (TTM) | 0.330 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 167.68% |
| Nisbah Semasa (MRQ) | 0.940 |
| Aliran Tunai Operasi (OCF TTM) | 7.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.40 M |
| Pulangan Atas Aset (ROA TTM) | 10.36% |
| Pulangan Atas Ekuiti (ROE TTM) | 503.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Champions Oncology, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.00 |
|
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 25.95% |
| % Dimiliki oleh Institusi | 49.51% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 15 Sep 2025 | Pengumuman | CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million |
| 15 Sep 2025 | Pengumuman | Champions Oncology Reports Record Quarterly Revenue of $14.0 Million |
| 10 Sep 2025 | Pengumuman | Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |